CymaBay Therapeutics (NASDAQ:CBAY) Announces Earnings Results, Misses Expectations By $0.01 EPS

CymaBay Therapeutics (NASDAQ:CBAY) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01), Yahoo Finance reports.

CBAY stock opened at $5.58 on Friday. The company has a quick ratio of 16.20, a current ratio of 16.20 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $4.98 and a two-hundred day moving average price of $7.53. The company has a market cap of $356.56 million, a price-to-earnings ratio of -4.43 and a beta of 1.25. CymaBay Therapeutics has a twelve month low of $4.23 and a twelve month high of $14.00.

In related news, CEO Sujal Shah purchased 5,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was purchased at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the chief executive officer now directly owns 111,900 shares in the company, valued at $618,807. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders acquired 11,900 shares of company stock valued at $59,600. Corporate insiders own 4.20% of the company’s stock.

A number of brokerages recently issued reports on CBAY. Cantor Fitzgerald set a $20.00 target price on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Wednesday, September 18th. Zacks Investment Research raised CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a research report on Tuesday, October 8th. BidaskClub raised CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating on shares of CymaBay Therapeutics in a research report on Wednesday. Finally, Evercore ISI restated a “buy” rating and issued a $15.00 price target on shares of CymaBay Therapeutics in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $13.25.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with's FREE daily email newsletter.